Q4 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Jagsonpal Pharmaceuticals Ltd (BOM:507789) reported a strong recovery in Q4 with a 14.2% growth, outperforming the industry growth of 10.5%.
- The company achieved a 12.2% growth on an MAT basis, outperforming the market by 3.6%.
- The company maintains a strong cash position with over Rs 190 crore, reflecting financial discipline.
- A 200% dividend, including a one-time special dividend of 75%, has been recommended, showcasing confidence in future growth.
- The company has a robust portfolio with 9 out of the top 10 brands ranked within the top 5 in their respective categories.
- Revenue growth for FY26 was modest at around 7%, which may not meet some investor expectations.
- There is a risk of over-aspiration on certain new product opportunities, which may not perform as expected.
- The company faces macroeconomic risks that could impact execution, although internally they are confident.
- Gross margins have seen a minor decline due to product mix issues, which could affect profitability.
- The company is returning significant cash to shareholders, which may raise concerns about the lack of reinvestment opportunities for growth.
Ladies and Gentlemen, good day and welcome to Jagsonpal Pharmaceuticals Limited Q4 and FY26 Earning Conference Call hosted by GoIndiaAdvisor.
(Operator Instructions).
Please note that this conference is being recorded.
Now hand the conference over to Ms. Soumya Chhajed.
Thank you and over to you ma'am.
Good evening, everyone and welcome to Q4 and FY26 earnings conference call of Jagsonpal Pharmaceuticals Limited. We have on call with us Mr. Manish Gupta, Managing Director; Mr. Amrit Medhekar, Chief Operating Officer and Mr. Nirav Vora, Chief Financial Officer.
We must remind you that the discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with risk pertaining to the business.
I now request the management to take us through the same and provide some more insight on the quarter and year gone by. Post that, we'll open the floor to Q&A.
Thank you, and over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
